Briefly, it was pointed out that, since none of the synthetic progestagens possessed all the properties of progesterone, and since these various properties are, in general, possessed in varying degree, a number of different criteria ought to be employed for tests of comparative potency. Unfortunately, few of these criteria provided data which permitted any approach to statistically valid quantitative comparisons, but the test which seemed most useful, at least as a screening procedure, was the postponement of menstruation assay, based on observations by Greenblatt et al. (1958) . In this test, it has become apparent that some, though not all, progestagens require the addition of cestrogen in order to be effective. The procedure is as follows: Normal women, with essentially regular menstruation, take the progestagen from the twentieth day of the cycle for twenty days. If menstruation is postponed until after the end of the course, the result is called positive and in the next cycle the dose of progestagen is halved. If aestrogen has been given in addition, its dose remains unchanged. Should the period occur before the twenty-day course is completed, the tablets are stopped, the result is called negative, and in the next cycle, the progestagen dose is doubled. By suitable dosage adjustment, the approximate 50%-effective dose (ED50) can be estimated. Swyer et al. (1960) reported the ED5Os of a number of progestagens as follows: Norethisterone 4-25, norethisterone acetate 10-25, norethynodrel+ethinyl cestradiol-3-methyl ether (Enavid) 5, norethynodrel alone approximately 15, 6ot-methyl-17oc-acetoxyprogesterone (Provera)+ethinyl aestradiol-3-methyl ether approximately 15, dimethisterone more than 80, 17oc-methallyl-19-nortestosterone more than 40 mg. Additional data have since been obtained and the up-to-date figures are shown in Table 1 . We can now also report on a number of 20 Norethynodrel+EE3ME (Enavid) 28 5-3 6a-methyl-17a-acetoxyprogesterone 4 >10 (Provera) 6a-methyl-17a-acetoxyprogesterone 21 22-5 +EE3ME approx. 9 ,, +EE3ME A6, 6-methyl-16-methylene, 17a-acetoxyprogesterone (BDH 1921) ,I, ',, +EE3ME 17 a-vinyl-1 9-nortestosterone (SC 4641) ,9, I, +EE3ME 21-fluoro, A6, 6-methyl-17a-acetoxyprogesterone (SC 10230)+EE3ME other progestagens, the results concerning which are shown in Table 2 . None of these substances appears to be effective in this test without added cestrogen. The most potent substances (with added cestrogen) tested so far are 17oc-ethinyl, cestr-4-ene-3, 17-dioldiacetate (SC 11800) with an ED50 of 1 5 mg, and A6, 6-methyl-17a.-acetoxyprogesterone (BDH 1298; SC 10363), with an ED50 of 1 8 mg; while the 16-methylene derivative of the latter (BDH 1921), though less active, is still a highly potent progestagen (ED50, 2-5 mg). From very limited data, it would seem that the 21-fluoro derivative (SC 10230) is also highly active. Isopregnenone (Duphaston) does not appear to be particularly potent in this test; our data are still only very limited but we have not obtained any positive responses with doses up to 20 mg alone and 10 mg with added cestrogen. 17ao-acetoxyprogesterone cyclopentyl-3-enol ether (Gestovis) is supplied in oily solution in capsules of 10 or 20 mg and we have therefore not been able to test below the 10 mg level, but our results suggest that, with added cestrogen, its potency is not much inferior to that of Enavid.
Further information of value in making clinical assessments of progestagens relates to inhibition of ovulation and cycle control. These studies are made by administering, to women with normal menstrual cycles, the progestagen, with or without added oestrogen, daily from the fifth day of the cycle for twenty days. The patient is instructed to collect the entire urine output over days 8 to 10 and days 20 to 22, the pregnanediol excretion being determined by the method of Klopper et al. (1955) . If ovulation has occurred, the pregnanediol content of the second urine pool would be expected to be some three or more times that of the first; while if ovulation has been inhibited no such difference would be expected. The justification of this technique requires that the progestagen administered is not metabolized to pregnanediol, and this is true for all progestagens so far tested with the sole exception of progesterone cyclopentyl-enol ether (Enol Luteovis). At the same time that evidence relating to inhibition is being collected, data are recorded on the length of the cycle, the occurrence of break-through bleeding and of intermenstrual spotting. Some of our data on cycle control and inhibition of ovulation are given in Table 3 and Fig 1. The effects, on cycle control, of varying the dose of progestagen and the proportion of cestrogen are illustrated by the studies on BDH 1298 (Table 3) . From the high incidence of breakthrough bleeding with SC 11800, in spite of its high potency in the postponement of menstruation test, it is clear that the results obtained in the latter do not give a guide to effectiveness of cycle control. This is further emphasized by the converse situation exemplified by Anovlar, which gives excellent cycle control though, in the postponement test, norethisterone acetate was found to have an ED50 of as much as 105 mg.
The data on inhibition of ovulation are selfexplanatory (Fig 1) . The single case treated with Gestovis (C1) was one of 3 tested, a continuous brown discharge or break-through bleeding on the fifteenth day of the cycle preventing completion of the study in the other 2. In one of the 2 cycles on l7ac-ethinyl-17,13-hydroxy-aestr-4-ene (Lynestrenol) with ethinyl aestradiol-3-methyl ether ovulation may have occurred. All 5 patients on isopregnenone appear to have ovulated; this confirms Bishop's report (1961) .
No attempt will be made in this paper to discuss the difficult subject of assessment of progestagens for the treatment of gynecological disorders or pregnancy maintenance. The need for more effective and acceptable methods of contraception is apparent from the high failure rates in all published reports of older methods; these have not proved generally acceptable or satisfactory in underdeveloped countries. According to M Peberdy (personal communication, 1962), and to Pullen (1962) , oral contraception with norethynodrel has proved more consistently effective even in women of low educational status and in others for whom older methods have been completely ineffective. During cyclic administration of adequate doses of norethynodrel and ethinyl cestradiol 3-methyl ether the ovary is in a state of quiescence. Corpora lutea have not been seen at laparotomies carried out in the second half of the cycle in women on continued cyclic medication (J Rock, personal communication, 1962) nor recent corpora lutea in early cycles of medication. Further supporting evidence for the mechanism of action comes from reduction in urinary pregnanediol excretion in the second half of treated cycles indicating absence of functioning corpora lutea. This is also supported by absence of the luteal thermogenic effect; this is a satisfactory indirect index of ovulation in untreated and cestrogen-treated cycles but not during administration of progestins as these may produce a thermogenic effect. Data from administration of norethynodrel (G I M Swyer, personal communication, 1961) for varying periods during the first half of the cycle suggest that the mechanism of action is related to the early phase of follicle development and not to specific events immediately preceding ovulation. This temporary arrest of follicle development resembles the situation which exists in normal pregnancy.
Speculation concerning other possible contraceptive effects of progestins are not applicable to norethynodrel. Progestins without (estrogenic action might prevent penetration of the cervical mucus by spermatozoa but penetration may occur with effective contraceptive dosage with norethynodrel (M C N Jackson, personal communication, 1962). The possibility that the type ofendometrium produced by norethynodrel might be unsuitable for implantation of the fertilized ovum is unlikely in view of the fact that normal implantation can occur in the similar endometrium produced by administration of norethynodrel after ovulation has occurred. Implantation can also occur in extrauterine sites, indicating that there is no necessity for a particular pattern of endometrial glandular development. In any case it should be noted that control of fertility by interference with implantation would represent an abortifacient rather than a contraceptive effect.
The possibility that cyclic administration of cestrogen alone might provide a method of oral contraception was rejected for three reasons:
(1) There may be a lack of continued effectiveness during repeated cyclic administration of a dose of oestrogen known to have inhibited ovulation in the first cycle or cycles. (2) Cycle control is unsatisfactory; the abnormalities to be expected are amenorrhcea and a tendency to heavy bleeding during continued cyclic administration in contrast with the tendency to reduced menstrual loss with progestins.
(3) There are theoretical long-term hazards related to the endometrial proliferation associated with aestrogens. Although experimental evidence suggests that these and other hypothetical problems are related to continuous rather than cyclic administration it is likely that they can be avoided by using progestins as these are known to block the proliferative effects of cestrogen administration. The use of progestin alone gives rise to poor cycle control characterized by shortening of the menstrual cycle due to breakthrough bleeding during cyclic administration. This tendency can always be lessened by adding cestrogen which can be expected to improve endometrial support during progestin administration under all known circumstances. This applies to cyclic use from days 5 to 24 as in oral contraception, to later in the cycle as in the postponement of menstruation assay (Swyer & Little 1962) and to continuous administration month after month for the pseudopregnancy treatment of endometriosis. It also applies at low, intermediate and high levels of progestin dosage. Combination with cestrogen thus increases the efficiency of progestational therapy in virtually every situation where the need for and value of the treatment can be clearly established.
In selecting and testing progestins for cyclic use with cestrogen for oral contraception, inevitable oestrogenic and progestational side-effects may be minimized by choice of optimal dosage. Other hormonal activities should be avoided. 17hydroxyprogesterone has an important place in the adrenal biosynthetic pathways, and potent orally active analogues with 6-substitution cause adrenal atrophy in animals. 19-nortestosterone derivatives are androgenic and cause cholestatic jaundice. Improvement has been achieved by modification of the A4 3 keto configuration in norethynodrel (A5 (10)) and SC 11800 (derived from 3-P alcohol). These compounds are cestrogenic and not androgenic, and jaundice attributable to them has not been reported. (Bromsulphthalein retention with norethynodrel and another A5 (10) compound is less than that encountered with the A4 analogues.) Non-aestrogenic progestins with extremely high potency in animal tests are sometimes disappointingly weak in the human. SC 11800 shows modest activity in animal tests but is five times as potent as norethynodrel in man.
Clinical testing of new progestins should include quantitative assessment of potency in the human. The only satisfactory method at present is the postponement of menstruation assay ). Confirmation of endometrial supporting activity should be obtained from demonstration of effectiveness in control of functional uterine bleeding. The standard ofsafety demanded before a compound is released for contraceptive use should be even higher than that acceptable for new drugs used in the treatment of disease. For this reason, it is reassuring to know that the actual compound offered to normal women has already been found safe when given in higher doses to thousands of gynecological patients, including long-term continuous treatment of endometriosis which may involve continuous long-term dosage twenty to sixty times greater than that now used for oral contraception. In addition, there is no alternative to extensive information from large-scale prolonged trials before a compound is released for use by normal women. Data on 2X5 mg norethynodrel tablets containing 0X1 mg of ethinylcestradiol 3-methyl ether include results obtained during the last three years in 1,500 women volunteers during over 9,000 cycles of medication. The overall effectiveness achieved is not significantly different from that achieved with 10 mg and 5 mg tablets. Overall data on norethynodrel include over 4,000 women and 60,000 cycles of tablet taking in controlled oral contraceptive trials, in addition to widespread experience of gynmcological use during the last seven years. Follow-up studies reported elsewhere (Cook et al. 1961 , Morris 1961 , Pincus 1961 , Tyler 1961 have included a wide range of clinical, hematological, biochemical and other laboratory investigations to exclude possible adverse effects. The great majority of women have.found oral contraception to be very acceptable and many have specifically emphasized their preference for this method.
Oral contraception with norethynodrel is based on imitation of the hormonal effects of normal human pregnancy during which further ovulation is consistently inhibited. The parallelism is a very close one, as shown by similarity of subjective and objective side-effects and other changes which may occur in healthy women and in disease states; almost every known effect of pregnancy has been reported with the use of norethynodrel either during oral contraception or at higher dose levels in gynecology. Although one cannot pre-dict the effects of twenty years' use from seven years' experience with norethynodrel there seems to be no logical reason to fear any hypothetical long-term risk in view of the apparent harmlessness of frequently repeated normal pregnancy. Oral contraception with norethynodrel appears to be as safe as pregnancy but without the special hazards associated with foetus, placenta and parturition.
Dr Margaret C N Jackson (Exeter)pointed out that there were quite striking differences in the clinical examination of patients taking norethynodrel as an oral contraceptive from day 5 for twenty days, from those taking one of the norethisterone tablets; this was true even when cestrogen was combined with the progestagen. In the former, cestrogenic influence appeared to be dominant, whereas in the latter the progestagen overruled the cestrogen. For example, patients on Conovid or Conovid E tended to have a higher cornification index in their vaginal smears and fairly plentiful elastic mucus throughout the cycle and in 50 % of the cases where spermatozoa were present they were motile, whereas in patients taking Anovlar the vaginal smears were predominantly progestagenic and their mucus tended to be scanty and tacky; spermatozoa, when present, were almost invariably immotile. Endometrium from these two groups also showed certain characteristic differences: in the norethynodrel cases glands were more plentiful and distended and cells were larger; subnuclear vacuolation was characteristically present right up to the fifteenth or sixteenth day on tablets, though during the last four days or so the glands tended to regress and become smaller. The stroma was moderately loose and cedematous and showed more or less well marked pseudodecidual response. In women on a norethisterone tablet the endometrium tended to be more hypoplastic and remained remarkably static throughout the twenty days; the glands were small and sparse, there was little distension and subnuclear vacuolation was only seen here and there and on a few days; the stroma was dense and fibrillar with pseudodecidual change towards the end of the twenty days. Profound atrophy of endometrium could occur with either preparation but recovery was usually rapid after release from tablet taking. The great variety of oral gestagens presently available make it necessary to have some criteria by which the clinician can discriminate between these compounds. The results from the use of a variety of synthetic gestagens in dysfunctional uterine hmmorrhage were therefore compared. These results were assessed in terms of their effect on the bleeding pattern, on endometrial biopsies, on the urinary excretion of cestriol and. pregnanediol and on the basal temperature.
It was found that in general terms the clinical characteristics of synthetic gestagens could be related to their chemical 'structure. There are four groups of these compounds having common features within each group, distinct from those of the other groups. These groups can be defined in terms of four parent compounds, testosterone, 1 9-nortestosterone, 1 7oc-hydroxyprogesterone or progesterone itself.
Of the gestagens related to testosterone, ethisterone has been in use for over twenty years and its clinical capacity is well known. Dimethylethisterone differs only in the addition of methyl groups at C6 and C21; it is more potent, weight for weight, than ethisterone but does not otherwise differ from it. Some examples of synthetic gestagens related to 19-nortestosterone are shown in Fig 1. It is very difficult in the case of the 19-nortestosterones to distinguish between their aestrogenic and their progestational properties. One. of them, norethynodrel, is dispensed with added oestrogen and another, norethisterone, has been shown to be partly transformed to cestrogen during its metabolism in the body. It is likely that all the 19-nortestosterone group are to some extent cestrogenic. They are characterized by being potent inhibitors of ovulation and by their haemostatic effect in active uterine bleeding of endocrine origin. These are both features also shown by many synthetic cestrogens. In two respects the effects of 19-nortestosterone derivatives can be shown to differ from cestrogens: the histological picture of the endometrium, although by no means a true progestational one, is different from that produced by cestrogens alone and the withdrawal bleeding which follows after the use of 19-nortestosterone compounds is much shorter and less severe than an cestrogen withdrawal bleeding. Steroid assays show that, given early in the cycle, the effect of 19-nortestosterone derivatives is to suppress all endogenous ovarian production of aestrogen and progesterone. The efficacy of 19-nortestosterone derivatives seems to depend upon this suppression of endogenous hormone production rather than on any direct effect of the gestagen on the endometrium. Judging by the degree of secretory transformation of the endometrium the 19-nortestosterone compounds are poor gestagens. They are, however, very potent at controlling excessive bleeding and no form of dysfunctional bleeding was encountered in which the bleeding could not be controlled by 19-nortestosterone derivatives. Unfortunately the effect is not permanent and when patients are taken off the steroids they tend to relapse into their previous menorrhagic pattern.
Compounds related to 1 7o-hydroxyprogesterone are shown in Fig 2. In all these compounds the hydroxyl group at C17 has to be eliminated by esterification before a progestationally active compound is produced. As a group the 1 7chydroxyprogesterone derivatives are much more variable than the 19-nortestosterone compounds, their clinical characteristics being much more dependent on what other substituents are added to the molecule. As regards their power to inhibit ovulation, the 17oc-hydroxyprogesterone derivatives show a gradient running from the acetate, the caproate and, possibly, the enol ether which do not inhibit ovulation, to 6x-methyl-17cxhydroxyprogesterone acetate which is weakly anovulatory and thence to the ICI and BDH compounds which have a modest power to inhibit ovulation. Their effect on the bleeding pattern follows the same gradient, and as a group they are not nearly so effective at controlling uterine hemorrhage as are the 19-nortestosterone compounds. The effect of 17o-hydroxyprogesterone derivatives on the endometrium is not at all correlated with their effect on bleeding. Some of these compounds, particularly the enol ether, produce a considerable degree of secretory transformation of the endometrium which can sometimes barely be distinguished from that of the late secretory phase of the normal cycle. If the production of a secretory endometrium plays any part in the treatment of dysfunctional uterine hkmorrhage it would be wise to combine 17oc-hydroxyprogesterone compounds with an cestrogen as there is no evidence that they have any cestrogenic activity of their own.
True progesterone derivatives are shown in Fig 3. Like the 17oc-hydroxyprogesterone compounds the progesterone derivatives have no cestrogenic activity and produce a secretory transformation of the endometrium. Their effect on the blood loss in dysfunctional uterine hemorrhage is small. Unless given in combination with oestrogens there does not seem to be any application for these compounds in the treatment of this condi- tion. On the whole it would appear that they might more usefully be applied to the treatment of such conditions as recurrent abortion or dysmenorrheea.
One of the progesterone derivatives, the cyclopentyl enol ether, is unique in being the only gestagen which gives rise to urinary pregnanediol. Its metabolism therefore resembles that of authentic progesterone and it is likely that this compound owes its activity to the slow release of progesterone itself in the circulation. This would particularly strongly indicate its use in recurrent abortion.
The value of a particular gestagen in the treatment of dysfunctional uterine hemorrhage can only -be assessed on the basis of an accurate diagnosis of the particular variety of the disease. Unfortunately no generally accepted classification of these hmemorrhages exists. The patients in the present series have been divided into three broad categories on the grounds of bleeding pattern and of endometrial histology: (1) Women bleeding from a secretory endometrium. These are usually parous women in their late 20s or early 30s. A fairly regular cycle is preserved, the main feature of the bleeding pattern being prolongation of the bleeding phase. The histological difference from a normal premenstrual endometrium is slight; it consists mainly in a greater degree of stromal cedema with a relative immaturity of the glands.
(2) Anovular bleeding occurs in older parous women in their late 30s. Some shortening of the cycle with lengthening of the bleeding phase may result in an impression that the bleeding is irregular, but if these patients are observed for some time in the untreated state it will be found that their cycles are reasonably regular. The premenstrual endometrium shows well-developed columnar glands with no evidence of secretory change.
(3) Cystic glandular hyperplasia of the endometrium has often been described. Our patients with this state showed a notable metrorrhagia with periods of amenorrhoea, sometimes a succession of regular cycles, and bouts of prolonged, occasionally very heavy, bleeding. In terms of the endometrial histology it would be reasonable to expect all these types to respond to progestational therapy. In fact, the effect of gestagens did not vary from one type of dysfunctional hxemorrhage to another. The results of gestagen therapy did not appear to depend on making good the missing or deficient progestational element but on the suppression of endogenous ovarian steroid production. Menorrhagia associated with ovular cycles was controlled when ovulation was suppressed by the exhibition of a suitable gestagen early in the cycle, and excessive bleeding associated with anovulatory cycles was prevented when ovarian cestrogen production was suppressed by gestagens. On the whole cystic glandular hyperplasia proved to be the most refractory form of dysfunctional uterine hwmorrhage but even when the cystic glandular state persisted to some degree, the induction of regular gestagen withdrawal bleedings resulted in satisfactory control of blood loss. Follow-up studies showed that all three types of dysfunctional hkmorrhage were equally liable to recur when steroid therapy was discontinued. The majority of patients reverted to their previous menorrhagic pattern and there was no clear evidence that gestagen therapy effected permanent cures in any type of dysfunctional hxemorrhage. Oral gestagens, particularly the I 9-nortestosterone compounds have, however, made a great improvement in the treatment of dysfunctional uterine haemorrhage.
Dr P M F Bishop (Chelsea Hospitalfor Women, London)
The Use of Oral Progesins in the Treatment of Dysmenorrhuea In 1940 Sturgis & Albright suggested that spasmodic dysmenorrhoea was due to the presence of endogenous progesterone and could be prevented by inhibiting ovulation. For many years this was successfully accomplished by giving oestrogen in the first half of the menstrual cycle. Bishop & Orti (1952) , for instance, treated 73 patients for 631 cycles with cestrogens, usually stilbeestrol 2 mg daily for fourteen days commencing within the first five days of the onset of bleeding, and studied basal temperature records in 148 of these cycles, finding that 87 % were non-ovulatory and painless. Pincus et al. (1958) employed oral progestins as contraceptive agents by inhibiting ovulation when administered from day 5 to day 25 of the cycle.
Interest in these orally active progestational compounds spread and they have been submitted to clinical trial by a number of workers. At the Endocrine Clinic at Chelsea Hospital for Women, 42 patients suffering from incapacitating dysmenorrheea, that is pain sufficiently severe to keep them in bed, absent from school or away from work and occurring in practically every cycle, -have been given oral progestins for 246 cycles. One of the following compounds was used in 24 cycles: cyclopentyl-3-enol ether of progesterone (Enol Luteovis), 6ao-methyl, 17oc-hydroxyprogesterone acetate with or without added ethinylestradiol 3-methyl ether (Protex, Intex, Perlutex), norethynodrel plus ethinyloestradiol 3-methyl ether (Enavid, Conovid), 6a.-chloro-6-dehydro-1 7mc-hydroxyprogesterone acetate (chlormadinone), 6cx, 21-dimethyl-17ox-ethinyltestosterone (dimethisterone: Secrosteron) and 17ot-allyl-17 ,hydroxy-estr-4-ene (allyleestrenol: Gestanin). Our main experience, however, has been with 170cethinyl-l9-nortestosterone (norethisterone : norethindrone: Primolut N) and 6-dehydro-retroprogesterone (dydrogesterone Duphaston).
Norethisterone was administered to 20 dysmenorrhoeic women in 102 cycles with the object of inhibiting ovulation and thereby causing painless uterine bleeding. In 9 cycles the course was begun on the eighth or subsequent days in the cycle, up to day 15, and was followed by painful bleeding on 8 occasions. Twenty-day courses commencing on day 5 were given, however, in 93 cycles. Break-through bleeding occurred on 6 occasions and one course was not followed by bleeding. In the remaining 86 cycles the subsequent period was painless in 73 % when the daily dose was less than 15 mg and in 90% when the daily dose was 15 or 20 mg (Table 1 ). In conjunctionwith Dr E Diczfalusy and Dr K G Tillinger, of the Karolinska Sjukhuset in Stockholm, and Professor U Borell, then of Oioteborg (now of Stockholm), we carried out clinical trials of the new compound 6-dehydroretroprogesterone (dydrogesterone : Duphaston) and among other observations we studied its effect in dysmenorrhaea. We assumed that, like other oral progestins, it might induce painless bleeding by inhibiting ovulation and our routine practice, therefore, was to administer it from day 5 to day 25. However, studies of basal temperature records (this compound, unlike some progestins, is not thermogenic) soon began to suggest that ovulation was taking place. This suggestion was supported by finding normal levels of urinary pregnanediol in the second half of the cycle (the compound itself is not excreted as pregnanediol) and was finally confirmed by observing fresh corpora lutea in the ovaries of patients submitted to laparotomy for fibroids, etc., during the second half of a dydrogesterone-treated cycle (Bishop et al. 1962 ).
In our Clinic at Chelsea Hospital for Women dydrogesterone was given to 32 dysmenorrhweic women in 120 cycles. Twenty-day courses commencing on day 5-7 were administered in 90 cycles. Break-through bleeding occurred in 14 cycles. Of the remaining 76 cycles the subsequent period was painless in 74% when the daily dose was less than 15 mg and in 85% when the daily dose was 15 or 20 mg (Table 1) .
It seems, therefore, although the mechanism of action is apparently different, that the results of administering norethisterone and dydrogesterone are very similar.
If dydrogesterone does not prevent painful bleeding by inhibiting ovulation it would seem unnecessary to commence treatment as early as day 5. In 30 cycles administration was started on day 8-16 and continued for nine to twenty days. Break-through bleeding occurred in 4 cycles. In the remaining 26 cycles the subsequent period was painless on 13 occasions (50%), in spite of the fact that the daily dose was generally as high and sometimes higher than in the cycles treated from day 5 to day 25.
Dysmenorrhoea is a subjective symptom and it could be argued that assessment of the efficacy of any drug in its treatment can be accurately achieved only by 'double blind' trial. Both in the case of norethisterone and dydrogesterone our primary object was to study the human pharmacology of the drug rather than its efficacy in the treatment of dysmenorrheea and consequently the double blind method was not adopted.
